AAIC 2020
27.07.2020 - 31.07.2020
VIRTUAL Conference
www.alz.org/aaic/overview.asp
"Discover our innovative platforms and proven solutions for advanced healthcare"
Join us on our virtual booth!
Shimadzu is a leading driver in developing healthcare solutions with technology developments ranging from advanced imaging systems for use in medical diagnosis and treatment, engineering mass spectrometry-based solutions for exploring ways to discover disease biomarkers as well as building MS solutions for daily routine quantitation in biological fluids. Discover all our solutions at the virtual booth!
Oral presentation ON-DEMAND
Title: Performances of the plasma Aβ biomarker in longitudinal data
Akinori Nakamura, National Center for Geriatrics and Gerontology, Japan
Tuesday, July 28, 2020: 12:00 AM - 11:59 PM (Q&A TIME 8:00 AM - 8:25 AM)
ON-DEMAND SESSIONS: Biomarkers (Non-Neuroimaging): Blood Based Biomarkers
Posters
Poster #47112
Developing Topic Posters: Biomarkers
Tuesday, July 28, 2020: 12:00 AM - 11:59 PM
Title: MALDI-TOF IP-MS quantification of plasma amyloid peptides in Alzheimer’s disease
Author: Sylvain Lehmann, CHU Montpellier, France
Poster #39194
Posters: Biomarkers
Tuesday, July 28, 2020: 12:00 AM - 11:59
Title: Identification of ADAMTS4 as an APP-cleaving enzyme at 669 site in APP669-711 production pathway
Author: Taisuke Tomita, The University of Tokyo, Japan
Poster #45810
Posters: Biomarkers
Tuesday, July 28, 2020: 12:00 AM - 11:59
Title: Studies on the Pragmatic Performance and Validity of a Plasma Amyloid β Measurement System by Immunoprecipitation-Mass Spectrometry
Author: Naoki Kaneko, Shimadzu Corporation, Japan
Poster # 45884
Posters: Clinical Manifestations/Biomarkers
Wednesday, July 29, 2020: 12:00 AM - 11:59 PM
Title: Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease
Author: Yen Ying Lim, The Florey Institute of Neuroscience and Mental Health, Australia
Other posters
Title: Immunoprecipitation-mass spectrometry (IP-MS) for plasma amyloid-β can be conducted with several kinds of monoclonal antibodies
Author: Ritsuko Yoda, Shimadzu Corporation, Japan
Posters: Biomarkers
Title: Analysis of the amyloid β-related peptides in mouse plasma and cell culture media
Author: Naoki Kaneko, Shimadzu Corporation, Japan
Posters: Biomarkers
Tiltle: Mass Spectrometric Quantification of Tau Protein Isoforms in Human Cerebrospinal Fluid
Author: Yusaku Hioki, Shimadzu Corporation, Japan
Posters: Biomarkers
Title: Immunoassay for Plasma APP669-711‚ One Component of the Amyloid β Biomarker
Author: Naoki Kaneko, Shimadzu Corporation, Japan
Posters: Biomarkers
Services
Shimadzu recently developed the Amyloid Mass Spectrometry (MS) Service — a new simple, low-cost blood test for early screening of amyloid-positive subjects. (RUO)
Product Lineup
An affordable, robust Linear MALDI-TOF mass spectrometry for all laboratories requiring routine manual or automated analysis of a wide variety of sample classes.
Used to detect presence and ratio of amyloid beta in blood samples after immunoprecipitation.
"Benchtop linear MALDI-TOF Mass Spectrometer" A high-performance benchtop linear MALDI-TOF Mass Spectrometer designed for routine MALDI-based workflows. Ideal to develop new tests and profiling solutions.
Sample throughput is increased using solid-state laser and traceability is insured by a unique patented barcode reader on the system.
The LCMS-8060NX is a triple quadrupole mass spectrometer with high-class sensitivity and detection speeds together with proven robustness.
A perfect tool for clinical research and quantitation of phosphor-TAU in biological fluids.
The quadrupole time-of-flight (Q-TOF) LCMS-9030 system is a research grade mass spectrometer designed to deliver high-resolution, accurate-mass detection with incredibly fast data acquisition rates, allowing scientists to identify and quantify more compounds with greater confidence.
LABNIRS & LIGHTNIRS - Toward Next-Generation Optical Brain-Function Imaging
Just how the human brain functions remain one of the greatest unsolved puzzles. To solve this mystery, brain-function imaging for visualization of brain functions has developed rapidly in recent years. In particular, in vivo optical imaging by functional near-infrared spectroscopy (fNIRS) has attracted attention as a technique that supports next-generation brain science.
Utilizing its leading-edge science and technology, Shimadzu has developed the LABNIRS/LIGHTNIRS, thereby contributing to the still growing field of brain science